Category: Abbott Laboratories
Abbott Vascular reportedly lays off 100 workers at a plant in Temecula, Calif.
Abbott Vascular (NYSE:ABT) is laying off about 100 workers at a California plant it acquired when it bought a portion of Guidant Corp. in 2006.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Medtronic unveils post-merger management structure; Abbott buys into electrophysiology with $250m Topera acquisition; Zimmer reveals post-Biomet merger plans; Medtronic, Covidien merger expected to close in 2015; Covidien deals Stellarex balloon to Spectranetics for $30m
Abbott pays $250 million plus milestones for Topera Medical and its cardiac arrhythmia mapping technology and inks a deal to acquire Advanced Cardiac Therapeutics and its ablation catheter.
Abbott says it will go ahead with its plan to deal its generic pharmaceuticals line to Mylan for $5.3 billion and reports 3rd-quarter sales in line with expectations.
Here's a look at some of the top regulatory stories for medical device companies this week: FDA yanks enhancement reporting requirement; FDA approves Medtronic's full-body MRI-safe lead; FDA strikes out again in Prevor drug-or-device case; Abbott inks co-distribution deal with Carl Zeiss Meditec; Boston Scientific wins CE Mark for Accolade MRI-safe pacemakers
Abbott says it inked a non-exclusive deal to sell Carl Zeiss Meditec's cataract surgery products alongside its own eye surgery offerings and announces FDA clearance for a pair of laser cataract surgery devices.
James Mazzo and Versant Ventures agree to suspend Mazzo after his indictment on insider trading charges stemming from Abbott's $2.8 billion acquisition of Advanced Medical Optics.
Versant Ventures and James Mazzo agreed that Mazzo will "suspend any activities" at the venture capital shop following his indictment last month on insider trading charges.